Vaxcyte Inc

PCVX is exhibiting a bearish pivot breakdown in a Stage 4 downtrend, with the recent failure to reclaim the 9 and 20 EMAs signaling a shift toward structural repair. Medium-term bias remains bearish, reinforced by price below the 50 SMA and the active Bearish Pivot Point pattern. Short-term rejection at the 9/20 EMA resistance zone confirms that timing favors selling into rallies. Selling now into the 59.99–60.10 zone aligns with the Momentum + EPS strategy’s preference for participating in momentum breakdowns.

• ↑Vax31 may boost serotype coverage 45%, capturing market share
• ↑$3.13B cash runway underwrites R&D and ops through 2025
• ↓R&D expenses forecasted at $480M in 2025, pressuring cash